These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 38610078)

  • 21. Adverse cardiovascular events in rheumatoid arthritis patients treated with JAK inhibitors: An analysis of postmarketing spontaneous safety reports.
    Goldman A; Galper BL; Druyan A; Grossman C; Sharif K; Shechtman L; Moshkovits Y; Lahat A; Ben-Zvi I
    Semin Arthritis Rheum; 2024 Aug; 67():152461. PubMed ID: 38772185
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Real-world single centre use of JAK inhibitors across the rheumatoid arthritis pathway.
    Fitton J; Melville AR; Emery P; Nam JL; Buch MH
    Rheumatology (Oxford); 2021 Sep; 60(9):4048-4054. PubMed ID: 33331938
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Janus kinase inhibitors for the treatment of rheumatoid arthritis demonstrate similar profiles of in vitro cytokine receptor inhibition.
    Dowty ME; Lin TH; Jesson MI; Hegen M; Martin DA; Katkade V; Menon S; Telliez JB
    Pharmacol Res Perspect; 2019 Dec; 7(6):e00537. PubMed ID: 31832202
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Repigmentation in vitiligo using the Janus kinase inhibitor tofacitinib may require concomitant light exposure.
    Liu LY; Strassner JP; Refat MA; Harris JE; King BA
    J Am Acad Dermatol; 2017 Oct; 77(4):675-682.e1. PubMed ID: 28823882
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinical efficacy of new JAK inhibitors under development. Just more of the same?
    Westhovens R
    Rheumatology (Oxford); 2019 Feb; 58(Suppl 1):i27-i33. PubMed ID: 30806706
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Safety of Janus Kinase Inhibitors in Patients With Inflammatory Bowel Diseases or Other Immune-mediated Diseases: A Systematic Review and Meta-Analysis.
    Olivera PA; Lasa JS; Bonovas S; Danese S; Peyrin-Biroulet L
    Gastroenterology; 2020 May; 158(6):1554-1573.e12. PubMed ID: 31926171
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Current jakinibs for the treatment of rheumatoid arthritis: a systematic review.
    Rocha CM; Alves AM; Bettanin BF; Majolo F; Gehringer M; Laufer S; Goettert MI
    Inflammopharmacology; 2021 Jun; 29(3):595-615. PubMed ID: 34046798
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Evaluation of discontinuation for adverse events of JAK inhibitors and bDMARDs in an international collaboration of rheumatoid arthritis registers (the 'JAK-pot' study).
    Aymon R; Mongin D; Bergstra SA; Choquette D; Codreanu C; De Cock D; Dreyer L; Elkayam O; Huschek D; Hyrich KL; Iannone F; Inanc N; Kearsley-Fleet L; Koca SS; Kvien TK; Leeb BF; Lukina G; Nordström DC; Pavelka K; Pombo-Suarez M; Rodrigues A; Rotar Z; Strangfeld A; Verschueren P; Westermann R; Zavada J; Courvoisier DS; Finckh A; Lauper K
    Ann Rheum Dis; 2024 Mar; 83(4):421-428. PubMed ID: 38071508
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A case of new-onset vitiligo in a patient on tofacitinib and brief review of paradoxical presentations with other novel targeted therapies.
    Nguyen JK; Schlichte MJ; Jogi R; Alikhan M; Patel AB
    Dermatol Online J; 2020 Mar; 26(3):. PubMed ID: 32609446
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Role of janus kinase inhibitors in the treatment of rheumatic diseases].
    Krüger K
    Internist (Berl); 2019 Nov; 60(11):1215-1220. PubMed ID: 31486859
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Repigmentation in vitiligo using janus kinase (JAK) inhibitors with phototherapy: systematic review and Meta-analysis.
    Phan K; Phan S; Shumack S; Gupta M
    J Dermatolog Treat; 2022 Feb; 33(1):173-177. PubMed ID: 32096671
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Janus kinase inhibitor tofacitinib does not facilitate the repigmentation in mouse model of rhododendrol-induced vitiligo.
    Hayashi M; Okamura K; Abe Y; Hozumi Y; Suzuki T
    J Dermatol; 2019 Jun; 46(6):548-550. PubMed ID: 30969438
    [No Abstract]   [Full Text] [Related]  

  • 33. Oral tofacitinib: a promising treatment in atopic dermatitis, alopecia areata and vitiligo.
    Vu M; Heyes C; Robertson SJ; Varigos GA; Ross G
    Clin Exp Dermatol; 2017 Dec; 42(8):942-944. PubMed ID: 29034491
    [No Abstract]   [Full Text] [Related]  

  • 34. JAK inhibitors are effective in a subset of patients with juvenile dermatomyositis: a monocentric retrospective study.
    Le Voyer T; Gitiaux C; Authier FJ; Bodemer C; Melki I; Quartier P; Aeschlimann F; Isapof A; Herbeuval JP; Bondet V; Charuel JL; Frémond ML; Duffy D; Rodero MP; Bader-Meunier B
    Rheumatology (Oxford); 2021 Dec; 60(12):5801-5808. PubMed ID: 33576769
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Treatment with Janus kinase inhibitors in juvenile dermatomyositis: A review of the literature.
    Sener S; Cam V; Ozen S; Batu ED
    Semin Arthritis Rheum; 2024 Jun; 66():152426. PubMed ID: 38442462
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Evaluation of ruxolitinib cream 1.5% as an at-home therapy for repigmentation in non-segmental vitiligo.
    Agner ML; Parraga SP; Arkhipenko ZM; Pichardo RO; McMichael AJ; Feldman SR
    Expert Rev Clin Immunol; 2024 Jul; 20(7):695-702. PubMed ID: 38879876
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Adverse drug events associated with 5mg versus 10mg Tofacitinib (Janus kinase inhibitor) twice daily for the treatment of autoimmune diseases: A systematic review and meta-analysis of randomized controlled trials.
    Huang F; Luo ZC
    Clin Rheumatol; 2019 Feb; 38(2):523-534. PubMed ID: 30242639
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparison of baricitinib, upadacitinib, and tofacitinib mediated regulation of cytokine signaling in human leukocyte subpopulations.
    McInnes IB; Byers NL; Higgs RE; Lee J; Macias WL; Na S; Ortmann RA; Rocha G; Rooney TP; Wehrman T; Zhang X; Zuckerman SH; Taylor PC
    Arthritis Res Ther; 2019 Aug; 21(1):183. PubMed ID: 31375130
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinical efficacy of launched JAK inhibitors in rheumatoid arthritis.
    Taylor PC
    Rheumatology (Oxford); 2019 Feb; 58(Suppl 1):i17-i26. PubMed ID: 30806707
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Janus Kinase Inhibitors for the Treatment of Severe Alopecia Areata: An Open-Label Comparative Study.
    Almutairi N; Nour TM; Hussain NH
    Dermatology; 2019; 235(2):130-136. PubMed ID: 30566941
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.